Floatz logo

Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta

Advanced Malignant Solid Neoplasm

Mayo Clinicgene_therapyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

124 Active assets in the Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Palbociclib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2BB
Vinorelbine
OHSU Knight Cancer Institute
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta is also rated in:

nonpapillary renal cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
angioimmunoblastic T-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →